We are thrilled to announce that Biovian will be exhibiting at the upcoming Oncolytic Virotherapy Summit, scheduled to take place from December 12-14 in the vibrant city of Boston, MA. As part of this summit, …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …
To display how Finland and Finnish solutions participate in the fight against cancer, Business Finland has compiled a new digital booklet, providing an overview of the extensive know-how and current areas of innovation. Biovian’s CDMO …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
Take Advantage of One-on-One Partnering! Schedule a virtual meeting with Magnus Gustafsson, the Head of Global Business Development of Biovian and find out how we can help your gene therapy or biopharma project from the …
The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …
